Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KLH and Tumor Lysate Pulsed Dendritic Cell Vaccine
- Development stage
- Unknown
- Lead developer
- Moffitt Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This is an autologous dendritic cell-based cancer vaccine developed by the H. Lee Moffitt Cancer Center and Research Institute for the treatment of high-risk neuroblastoma. The vaccine is prepared by harvesting a patient's peripheral blood monocytes, which are then matured into dendritic cells (DCs) using granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). These DCs are subsequently pulsed with both autologous tumor lysate, which provides a broad spectrum of tumor-associated antigens, and keyhole limpet hemocyanin (KLH), which serves as an immunogenic helper protein to enhance the immune response. The vaccine is designed to stimulate a T-cell mediated immune response against neuroblastoma cells. It is currently being evaluated in Phase 1 clinical trials in combination with autologous hematopoietic stem cell transplantation to reduce the risk of relapse.
- Other names
- KLH and Tumor Lysate Pulsed DC VaccineKLH + Tumor Lysate Pulsed DC VaccineDendritic Cell Vaccine for Neuroblastoma (Moffitt)
Beyond the preview
Go deeper on KLH and Tumor Lysate Pulsed Dendritic Cell Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KLH and Tumor Lysate Pulsed Dendritic Cell Vaccine.